Here we confirm that targeting the MAPK pathway with the MEK inhibitor PD-901 and targeting the PI3K/AKT/mTOR pathway with the mTOR inhibitor Everolimus is effective at inhibiting cellular growth in both NF1-assscociated and spontaneous MPNST cell lines in vitro, and that these inhibitors appear to act cytostatically. The gene discussed is MAP2K7; the disease is malignant peripheral nerve sheath tumor.